Skip to main content
. 2018 Jul 6;45(4):264–270. doi: 10.1159/000490858

Table 2.

Exploration of RHD and RHCE in 1,148 patients from late 2014 to 2017a

Parisian area Guadeloupe French Guiana Other mainland regions All regions
Patients with ≥ 1 partial RH antigen / 123 / 466 69 / 394 41 / 221 20 / 70 253 / 1,148
number of patients (%) (26.5%) (17.5%) (18.6%) (29.4%) (22.0%)
Number of partial RH1 / all RH:1 47 / 450 46 / 375 32 / 213 6 / 66 131 / 1,104
patients (%) (10.4%) (12.3%) (15.0%) (9.1%) (11.9%)
Number of partial RH2 / all RH:2 70 / 185 21 / 126 8 / 60 8 / 19 107 / 390
patients (%)* (37.8%) (16.7%) (13.3%) (42.1%) (27.4%)
Number of RH:3 patients 77 86 36 9 208
Number of partial RH4 / all RH:4 7 / 451 2 / 388 3 / 220 3 / 68 15 / 1,126
patients (%) (1.6%) (0.5%) (1.4%) (4.4%) (1.3%)
Number of partial RH5 / all RH:5 26 / 462 25 / 392 13 / 220 7 / 68 71 / 1,141
patients (%) (5.6%) (6.4%) (5.9%) (10.3%) (6.2%)
a

Detection of partial RH antigens following implementation of the French strategy. No partial RH3 antigen was detected. RH antigens for which weak expression could not be explained after RH genotyping with our strategy are included, as this weak antigen expression could be due to rare undetected RH alleles.

*

See table 3 for further details concerning RH2 alleles.